Development of the natural history component of an early economic model for primary sclerosing cholangitis
We have developed a model framework to simulate the progression of PSC with estimates of overall and transplant-free survival. This model, which calibrates well with existing estimates of disease progression, may be useful to evaluate the clinical and economic benefits of future treatments.
Authors
- Nandita Kachru (ORCID: https://orcid.org/0000-0002-2754-0723)
- Christopher L. Bowlus (ORCID: https://orcid.org/0000-0002-3906-6811)
- Daniel A. Ollendorf (ORCID: https://orcid.org/0000-0001-6016-8129)
- Sushanth Jeyakumar
- Mark Sculpher (ORCID: https://orcid.org/0000-0003-3746-9913)
- Cynthia Levy (ORCID: https://orcid.org/0000-0001-5498-6037)
- Yael Rodríguez‐Guadarrama
- Kris V. Kowdley (ORCID: https://orcid.org/0000-0002-8553-3652)
- Andrew Briggs
- Nathaniel Smith
Institutions
- Tufts Medical Center (US)
- University of Miami (US)
- Liver Institute Northwest (US)
- Gilead Sciences (United States) (US)
- University of California, Davis (US)
Publication Details
- Journal
- Orphanet Journal of Rare Diseases
- Published
- 2025-03-18
- DOI
- https://doi.org/10.1186/s13023-025-03658-8
- Citations
- 1
- Primary Topic
- Liver Diseases and Immunity
- Type
- article
- Field-Weighted Citation Impact
- 1.32
Funders
- Pfizer
- Gilead Sciences
- Intercept Pharmaceuticals
- NGM Biopharmaceuticals
- Novo Nordisk
- Ipsen